Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants.
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2016
At a glance
- Drugs MVA 85A (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 07 Feb 2013 Planned number of patients changed from 2784 to 2794.
- 04 Feb 2013 Results published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History